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https://doi.org/10.1016/j.cell.2020.09.016SUMMARYSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is typically very mild and often
asymptomatic in children. A complication is the rare multisystem inflammatory syndrome in children (MIS-
C) associated with COVID-19, presenting 4–6 weeks after infection as high fever, organ dysfunction, and
strongly elevatedmarkers of inflammation. The pathogenesis is unclear but has overlapping featureswith Ka-
wasaki disease suggestive of vasculitis and a likely autoimmune etiology.We apply systems-level analyses of
blood immune cells, cytokines, and autoantibodies in healthy children, children with Kawasaki disease
enrolled prior to COVID-19, children infected with SARS-CoV-2, and children presenting with MIS-C. We
find that the inflammatory response in MIS-C differs from the cytokine storm of severe acute COVID-19,
shares several features with Kawasaki disease, but also differs from this condition with respect to T cell sub-
sets, interleukin (IL)-17A, and biomarkers associated with arterial damage. Finally, autoantibody profiling
suggests multiple autoantibodies that could be involved in the pathogenesis of MIS-C.INTRODUCTION
The severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) first emerged in Wuhan in December 2019 (Huang
et al., 2020) and then spread rapidly to a number of countries
and, in particular, to Europe and the northern regions of Italy in
the early weeks of February 2020. The first reports from China
showed that children presented with milder symptoms as
compared to adults infected by SARS-CoV-2 (Lu et al., 2020).
Reasons for this have not been established, but several theories
have been discussed, involving immune systemdifferences such
as thymic function, cross-reactive immunity to common cold co-
ronaviruses, as well as differences in the expression of the viral
entry receptor ACE2, as well as a better overall health status
among children as compared to the elderly (Brodin, 2020). The
mild COVID-19 in children has been confirmed also in areas968 Cell 183, 968–981, November 12, 2020 ª 2020 The Author(s). Pu
This is an open access article under the CC BY license (http://creativewith high disease prevalence such as northern Italy (Parri et al.,
2020). The view that COVID-19 disease course is always mild
in children is now challenged by recent reports of children pre-
sentingwith a rare, but very severe hyperinflammatory syndrome
in the United Kingdom (Riphagen et al., 2020; Whittaker et al.,
2020), Italy (Verdoni et al., 2020), Spain (Moraleda et al., 2020),
and New York City (Cheung et al., 2020). In these case series,
children present with high fevers, and a variable number of
symptoms previously associated with Kawasaki disease such
as conjunctivitis, lymphadenopathy, mucocutaneous rash, and
coronary artery dilation, and in the most severe cases, cardio-
vascular shock, encephalitis, and multiple organ failure.
Kawasaki disease is a vasculitis affecting medium-sized ar-
teries with highest incidence in children younger than 5 years
old, and it is the leading cause of acquired heart disease in devel-




Kawasaki disease (2017-18) MIS-CHealthy children
Antibodies Plasma cytokinesImmune cells
n = 28
n = 41
n = 13n = 19
A
B
Children with COVID-19  (n = 54)
Kawasaki (n = 28) Healthy (n = 19) p-value
CoV-2+ (n = 41) MIS-C (n = 13)
Age in months  79.8  (11.5 - 131.1) 106  (71.1 - 165.4) 24.5  (15.8 - 41.8) 29 (21 - 45.8)
p = 0.04 (CoV-2+ vs MIS-C)  
p < 0.001 (CoV-2+ vs HC, KD) 
p < 0.001 (MIS-C vs HC, KD)
Male : Female 23 : 18 8 : 3 14 : 14 5 : 7 n.s.
Platelets, 109/L 252  (204.8 - 298.5) 163  (126.5 - 193.5) 378  (271.5 - 485.2) 372 (294 - 408.2) p < 0.001 (CoV-2+ vs rest)  p < 0.001 (MIS-C vs HC, KD)
WBC, 109/L 6.4  (5.2 - 9.1) 7.9  (5.5 - 8.7) 15  (11 - 19) 9.2 (7.9 - 9.7)
p < 0.001 (CoV-2+ vs KD) 
p < 0.001 (MIS-C vs KD) 
p < 0.001 (KD vs HC)
Neutrophils, 109/L 2.6  (1.8 - 3.9) 6.1  (4.3 - 7.5) 10  (6.5 - 12.7) 2.5 (1.9 - 3.7)
p = 0.004 (CoV-2+ vs MIS-C)  
p < 0.001 (CoV-2+ vs KD) 
p = 0.008 (MIS-C vs HC) 
p = 0.009 (MIS-C vs KD) 
p < 0.001 (KD vs HC)
Lymphocytes,109/L 2.6  (1.9 - 4) 0.7  (0.4 - 1.2) 2.4  (1.4 - 4.1) 4.7 (3.8 - 5.7)
p < 0.001 (CoV-2+ vs MIS-C)  
p = 0.004 (CoV-2+ vs HC)  
p < 0.001 (MIS-C vs HC, KD) 
p = 0.016 (KD vs HC)
Hb, g/dL 13  (12 - 13.9) 12.2  (10.6 - 14.8) 10.8  (10.3 - 11.2) 11.9 (11.4 - 12.3)
p = 0.014 (CoV-2+ vs HC) 
p < 0.001 (CoV-2+ vs KD) 
p = 0.001 (KD vs HC)
CRP, mg/dL 0.1  (0 - 0.5) 22.8  (18.2 - 26.5) 11.3  (8.1 - 18.8) 0 
p < 0.001 (CoV-2+ vs rest)  
p < 0.001 (MIS-C vs HC) 
p < 0.001 (KD vs HC)
Ferritin, ng/mL 58  (40 - 114) 550  (360.5 - 843) 186  (142.5 - 248.5) n.a.
p < 0.001 (CoV-2+ vs MIS-C)  
p = 0.003 (CoV-2+ vs KD) 
p < 0.001 (MIS-C vs KD)
Albumin, g/dL 4.3  (4.2 - 4.6) 29  (13.1 - 30.5) 3.7  (3.4 - 3.9) n.a.
p = 0.001 (CoV-2+ vs MIS-C)  
p < 0.001 (CoV-2+ vs KD) 
p < 0.001 (MIS-C vs KD)
Sodium, mEq/L 139  (138 - 140) 133.5  (132.2 - 136.5) 136  (134 - 137) n.a. p < 0.001 (CoV-2+ vs MIS-C, KD) 
Triglicerides,mg/dL 122.5  (73 - 158.5) 146  (126.2 - 171.8) 169.5  (117 - 229) n.a. p = 0.042 (CoV-2+ vs KD)
ALT, UI/L 18  (12 - 22) 20  (16 - 30) 38.5  (23 - 58.2) n.a. p < 0.01 (CoV-2+ vs KD) p = 0.041 (MIS-C vs KD)
AST, UI/L 26  (21.2 - 38.8) 26  (25.5 - 30.5) 33  (28.2 - 49.2) n.a. n.s
(legend on next page)
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Kawasaki disease has a particularly high incidence in children
with East Asian ancestry and was first described in Japan. The
dominating theory for the pathophysiology of Kawasaki disease
involves the production of self-reactive antibodies during an
acute immune response to a viral infection, probably at mucosal
surfaces and focused around IgA-producing plasma cells. Such
cells have also been found within the arterial wall in specimens
from children with Kawasaki disease (Rowley et al., 2008).
Neutrophils infiltrate the arterial wall, and a necrotizing arteritis
develops leading to the destruction of the connective tissue
and arterial dilation in severe cases (Shulman and Rowley,
2015). Efforts to define the pathogenesis of Kawasaki have
also revealed an imbalance of interleukin (IL)-17-producing
T cells and regulatory T cells during the acute phase of this dis-
ease (Jia et al., 2010).
Given the severity of the multisystem inflammatory syndrome
in children (MIS-C) associated with COVID-19 and the uncertain
development of the ongoing pandemic, there is an urgent need
to understand the pathogenesis of MIS-C, and its similarities
and differences with Kawasaki disease, so that optimal treat-
ment strategies can be devised. Here, we have performed a sys-
tems-level analysis of immune cells, cytokines, and antibodies in
the blood of children presenting withMIS-C as compared to chil-
dren with mild SARS-CoV-2 infection, children with Kawasaki
disease, and healthy children enrolled prior to the COVID-19
pandemic (Figure 1A). We reveal several details of the hyperin-
flammatory state in children with MIS-C, contrasting with both
the hyperinflammation seen in adults with acute SARS-CoV-2
infection, as well as that of children with Kawasaki disease. We
define key cytokine mediators, assess serological responses to
SARS-CoV-2 and other viruses, and we identify putative autoan-
tibody targets possibly involved in the pathogenesis of this new
disease.
RESULTS
Children with SARS-CoV-2, MIS-C, and Kawasaki
Disease
We enrolled 41 children with acute SARS-CoV-2 infection in
Rome, Italy, all with mild disease, and denote these as CoV-2+
children throughout this manuscript (Figure 1B).We also enrolled
three children presenting with MIS-C in Rome and 10 children
presenting with MIS-C in Stockholm, Sweden. We compare
these children with 28 children presenting with Kawasaki dis-
ease prior to the COVID-19 pandemic (March 2017 to May
2019). The children with MIS-C were significantly older than chil-
dren with Kawasaki disease (Figure 1B), in line with previous re-
ports (Whittaker et al., 2020). No significant sex-differences were
found among the groups of children. Both MIS-C and CoV-2+
children presented with lower white blood cell counts (WBC)
as compared to patients with Kawasaki disease and healthy chil-Figure 1. Systems-Level Analyses in Children with COVID-19, Kawasa
(A) Groups of children studied.
(B) Clinical parameters shown as median values (25th to 75th centiles). t test (para
values across groups of children.
970 Cell 183, 968–981, November 12, 2020dren (Olin et al., 2018; Figure 1B). Lymphopenia is a hallmark of
COVID-19 and was more pronounced in MIS-C than in children
withmild SARS-CoV-2 infection or Kawasaki disease (Figure 1B).
MIS-C patients also had markedly higher levels of C-reactive
protein (CRP) and ferritin and lower platelet counts as compared
to both Kawasaki disease patients and CoV-2+ children (Fig-
ure 1B). These observations are in line with recent clinical reports
on MIS-C (Dufort et al., 2020; Feldstein et al., 2020; Whittaker
et al., 2020), suggesting that our cohort is representative of re-
ported patients with MIS-C, Kawasaki disease, and children
with mild SARS-CoV-2-infection.
Hyperinflammation during MIS-C Differs from that of
Severe, Acute COVID-19
In adults and the elderly, themain cause of severe COVID-19 dis-
ease and death is uncontrolled immune activation, hyperinflam-
mation, and immunopathology (Vardhana and Wolchok, 2020).
This life-threatening response requires urgent management,
and the immunological aspects of this process are under intense
investigation (Kuri-Cervantes et al., 2020; Mathew et al., 2020). A
number of clinical trials are ongoing to test immunomodulatory
strategies that can calm the cytokine storm in severe COVID-
19. Because MIS-C is also a hyperinflammatory condition asso-
ciated with COVID-19, albeit with a delayed presentation, we
wondered whether the hyperinflammatory response in MIS-C
is similar to that seen in adults with severe COVID-19 disease.
Wemeasured 180 plasma proteins involved in immune response
and inflammation in serum samples from children with mild MIS-
C and Kawasaki disease and compared these to the cytokine
profiles in adults with severe acute COVID-19 and hyperinflam-
mation (Rodriguez et al., 2020). After filtering out proteins with
>30% measurements below the threshold of detection, we per-
formed principal component analysis (PCA) including 120 unique
proteins (Figure 2A; Table S1). Adults with acute COVID-19, both
patients in the intensive care unit (ICU) and floor (non-ICU), but all
severely ill, had very different cytokine profiles from those seen in
children with either MIS-C or Kawasaki disease (Figure 2A). The
main contributing features explaining this difference included IL-
8 (Figure 2B), a chemokine recently shown to be associated with
lymphopenia in severe COVID-19 cases (Zhang et al., 2020). IL-7
was also higher in acute COVID-19 hyperinflammation than in
MIS-C and Kawasaki disease, IL-7 is a cytokine involved in
T cell maintenance and associated with lymphocyte counts (Fig-
ure 2B). The MIS-C and Kawasaki hyperinflammatory states
partially overlapped and both differed from adults with acute
COVID-19 hyperinflammation (Figure 2A).
Differences in T Cell Subsets in MIS-C and Kawasaki
Disease
To better understand the hyperinflammation inMIS-C and Kawa-
saki disease, we assessed peripheral blood mononuclear cell
(PBMC) phenotypes by flow cytometry. Samples were collectedki Disease, and MIS-C






















































Figure 2. MIS-C Hyperinflammation Differs from Severe Acute COVID-19 Hyperinflammation
(A) Principal components 1 and 2 show variation in cytokine profiles among adult COVID-19 patients with severe disease treated in intensive care units (ICU) or
not, and children with MIS-C or Kawasaki disease. n = 97 samples included, and 112 unique proteins included in the analysis.
(B) Top 20 proteins mostly contributing to the PCs 1–2.
See also Table S1.
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OPEN ACCESSArticleat hospital admission, prior to treatment, and reflect cellular
states during the hyperinflammatory immune response. We
found differences in the distributions of subpopulations of
CD4+ T cells as defined by the expression of CD45RO and
CD27, and the frequency of T-follicular helper cells (TFH) ex-
pressing the chemokine receptor CXCR5 (Figure 3A). Total
T cell frequencies were lower in both types of hyperinflammatory
patients, MIS-C, and Kawasaki disease as compared to healthy
children (Figure 3B). Within the CD4+ T cell compartment, MIS-C
patients and children with mild SARS-CoV-2+ infection had
similar subset distributions, indicating that differences seen in
relation to healthy children could be related to the SARS-CoV-
2 infection itself (Figures 3C–3E). Both groups of patients that
experienced SARS-CoV-2 had higher abundances of central
memory (CM) and effector memory (EM) CD4+ T cells, but fewer
naive CD4+ T cells as compared to Kawasaki disease patients
(Figures 3C–3E). Follicular helper T cells, important players in
germinal center reactions and supporters of B cell responses,
were reduced in SARS-CoV-2 experienced children, both with
and without MIS-C, but not in Kawasaki disease patients (Fig-
ure 3F). CD57 marks terminally differentiated effector CD4+
T cells and these have been shown to be reduced in adult pa-
tients with severe acute COVID-19 and acute respiratory distress
syndrome (Anft et al., 2020). In children with mild COVID-19 and
children with MIS-C, we find higher levels of these terminally
differentiated cells when comparing to Kawasaki disease pa-
tients and healthy children (Figure 3G). We find that CD4
T cells (mostly CD8+ T cells) were significantly lower in MIS-C
children as compared to children with mild SARS-CoV-2 infec-
tion (Figures S1A–S1D). These results further emphasize thatthe hyperinflammation seen in acute, severe COVID-19 in adults
differs from that seen in MIS-C and also indicates some specific
differences between immune cell responses in MIS-C and pa-
tients with Kawasaki disease occurring prior to the COVID-19
pandemic.
Unraveling the Cytokine Storm in MIS-C and Kawasaki
Disease
To further investigate the hyperinflammatory immune states in
MIS-C and Kawasaki disease patients, we performed Olink as-
says on plasma samples from 11 children with MIS-C and 28
children with Kawasaki disease. We measured 180 unique pro-
teins using two Olink panels (Key Resources Table) and filtered
out proteins with >30% measurements below the threshold of
detection, resulting in 125 plasma proteins used for PCA (Fig-
ure 4A; Table S2). We find that healthy children and children in-
fected with SARS-CoV-2, without MIS-C, mostly overlapped,
illustrating the mild infection and low-grade inflammatory
response in these CoV-2+ children (Figure 4A). As shown by
the blown up PC2 versus 3 plot, MIS-C hyperinflammatory states
differ from that of Kawasaki disease (Figure 4A). PC2 best
discriminated these hyperinflammatory states in MIS-C and
Kawasaki disease, and we focused on the contributing features
(loadings) of PC2 (Figure 4B). We find that elevated IL-6, IL-17A,
CXCL10 contributed the most to the cytokine storm (Figure 4C).
IL-17A is important in Kawasaki disease (Jia et al., 2010), but was
significantly lower in MIS-C patients, indicating a difference in
the underlying immunopathology (Figure 4C). In contrast, the
top negative contributors were adenosine deaminase (ADA),



































































































































































































































































































































































































































































































































Gated on live CD3+ CD4+ T-cells
Figure 3. CD4+ T Cell Subsets in COVID-19 and MIS-C
(A) Gating schema to identify CD4+ T cell subsets from peripheral blood mononuclear cells.
(B) CD4+ T cells as a fraction of lymphocytes. Black lines indicate statistical tests and p values across indicated populations.
(C–G) Fraction of (C) CD4+ Tcm, (D) CD4+ Tem, (E) naive CD4+, (F) pTFH, and (G) CD57
+ CD4+ T cell subsets (%) in the indicated patient group. Black lines indicate
statistical tests and p values across indicated populations.
See also Figure S1.
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OPEN ACCESS Articleinterferon (IFN)g and Th1-type immune response (Maecker et al.,
2005). As a regulator of angiogenesis, TWEAK is also an inter-
esting finding given the vasculitis component of Kawasaki dis-
ease and probably also MIS-C (Figure 4D).
We also identified additional plasma proteins distinguishing
MIS-C from Kawasaki. Apart from IL-17A, DCBLD2, also called
ESDN, was more elevated in Kawasaki disease than MIS-C.
This protein has been shown to be secreted by endothelial cells
attacked by allogeneic immune cells after heart transplantation
(Sadeghi et al., 2007) and in balloon-dilated carotid arteries (Ko-
buke et al., 2001) suggestive of more pronounced arterial dam-
age in Kawasaki than in MIS-C. Collectively, these findings indi-
cate more arterial involvement in Kawasaki than MIS-C and also
an IL-17A-driven cytokine storm in Kawasaki disease but not in
MIS-C. IL-17-blocking agents are used in psoriasis and other
diseases and could also be of interest for future clinical trials in
these patients. Moreover, other key proteins differing among
these groups are MMP-1 and MMP-10 (Figure S2A), proteins
involved in arterial disease (Martinez-Aguilar et al., 2015), which972 Cell 183, 968–981, November 12, 2020is intriguing given the likely arterial inflammation component of
both MIS-C and Kawasaki disease.
MIS-C Immune Profiles Intersect Mild COVID-19 and
Kawasaki Disease andChange upon Immunomodulation
To understand the interaction among different immune system
components and their coregulation, we applied multiomics fac-
tor analysis (MOFA) (Argelaguet et al., 2019) to integrate T cell
subset frequencies and plasma protein concentrations from
MIS-C patients, Cov-2+ children, and children with Kawasaki
disease. We identified 10 latent factors that explain the com-
bined variance across cell and protein datasets (Figures S1D
and S1E). The first factor separated Kawasaki disease samples
from both groups of SARS-CoV-2 infected children (MIS-C and
CoV-2+) (Figure S1F). Conversely, factor 5 discriminated the ex-
tremes of Kawasaki versus mild SARS-CoV-2+ infections and
placed MIS-C samples in between these polar opposites (Fig-
ures S1G and S1H), indicating that the immunopathology in
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Figure 4. Cytokine Profiles in MIS-C and Kawasaki Disease
(A) Principal component analysis of top 5 components explains 58.3% of the variance in concentrations of 133 plasma proteins. PC2 versus 3 separate children
with Kawasaki (n = 28) from MIS-C (n = 11), healthy children (n = 12), and SARS-CoV-2+ children without hyperinflammation (n = 41).
(B) Proteins explaining (highest loading for) PC2.
(legend continued on next page)
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disease.
MIS-C patients are treated with strong immunomodulatory
agents. The treatment regimens for the 13 MIS-C patients in
our cohort are shown in Figure 5A. Most patients were treated
by high dose steroids in combinations with intravenous immuno-
globulins (IVIG) to override the effect of autoantibodies and stim-
ulate inhibitory Fc-receptors (Figure 5A). A number of children
were also given recombinant IL1RA (anakinra) to block IL-1a/b-
mediated inflammation (Figure 5A). We assessed the cytokine
changes upon treatment and found that tumor necrosis factor
beta (TNF-b), ITGA11, and CCL25 levels decreased, whereas
HEXIM1, PSP1, and CXCL10 levels increased in response to
treatment in the seven MIS-C patients with available pre/post
samples (Figures 5B and 5C). These results indicate that there
is a particular cytokine profile associated with MIS-C, which dif-
fers fromKawasaki disease hyperinflammation and that changes
in response to immunomodulatory treatment.
Serologic Responses and Pre-existing Humoral
Immunity in MIS-C
Given that Kawasaki disease and possibly also MIS-C display
autoantibody-mediated immunopathology, we decided to test
immunoglobulin G (IgG) responses to the SARS-CoV-2 virus in
these patients. We measured IgG binding of the receptor-bind-
ing domain (RBD) of the spike protein from SARS-CoV-2. We
found that the majority of children in our cohort testing positive
for infection by PCR also seroconverted (Figure 6A). We also
found that 3 out of 4 tested MIS-C patients seroconverted and
had comparable levels of SARS-CoV-2 IgG antibodies to the
spike protein as the children with mild SARS-CoV-2 infection
and no MIS-C (Figure 6A). This result is in line with data from
other groups studying antibody responses in MIS-C patients
(Gruber et al., 2020; Rostad et al., 2020). A possible hypothesis
for why some children develop MIS-C is that prior immunity to
other viruses could modulate their responses to SARS-CoV-2
infection and give rise to hyperinflammation either by antibody-
mediated enhancement or other mechanisms (Tetro, 2020). To
assess this, we applied VirScan, a phage display method for
testing IgG binding of 93,904 epitopes from 206 different viruses
able to infect human cells (Xu et al., 2015). We found that the chil-
dren in our cohort had IgG antibodies to common viruses such as
respiratory syncytial virus (RSV) and rhinovirus as well as viruses
of the herpesvirus family (Figure 6B). This is in line with our pre-
vious results (Pou et al., 2019). The common cold coronaviruses
are particularly interesting as possible modulators of immune re-
sponses to SARS-CoV-2 given their similarities. We focused on
IgG antibodies to these viruses in MIS-C, CoV-2+, healthy, and
Kawasaki-disease children. We found that IgG antibodies to hu-
man coronavirus HKU1 was commonly observed, as were anti-
bodies to betacoronavirus 1, but the MIS-C patients were the
only ones lacking antibodies to either of these common corona-(C and D) Raw (NPX) values for top (C) positive and (D) negative proteins (loading)
children.
(E) Raw (NPX) values of three proteins significantly different between Kawasak
disease children.
See also Figure S2 and Table S2.
974 Cell 183, 968–981, November 12, 2020viruses (Figure 6C). The relevance of this difference remains to
be determined; this could either reflect the fact that the MIS-C
patients are older than the other groups of children analyzed,
but it is also possible that the lack of IgG antibodies to common
coronaviruses modulates the immune response to SARS-CoV-2
infection and plays a role in the pathogenesis of MIS-C.
Proteome Array Profiling Reveals Potentially
Pathogenic Autoantibodies in MIS-C
Several studies have proposed autoantibodies as an element of
the immunopathology of Kawasaki disease (Sakurai, 2019). An
external trigger, likely in the form of a virus, is indicated by epi-
demics of Kawasaki disease, and direct evidence of antiviral
antibody responses, particularly targeting viral particles in inclu-
sion bodies in the respiratory epithelium, have been reported
(Rowley et al., 2008). Autoantibodies targeting endothelial cells
can activate IL-6 production by such cells in vitro (Grunebaum
et al., 2002), but a possible role of autoantibodies in MIS-C is un-
known. To search for such autoantibodies in MIS-C, we
screened serum samples from children with MIS-C (n = 12),
Kawasaki disease (n = 28), SARS-CoV-2+ infection (n = 5), as
well as healthy control children (n = 11). We probed serum sam-
ples against 9,341 human antigens from 7,669 unique human
proteins using protein arrays (Zhu et al., 2001) (ProtoArray
v5.1, PAH05251020, ThermoFisher, Waltham, MA). As ex-
pected, the autoantibody signals were low for the vast majority
of antigenic targets (Landegren et al., 2016; Figure 7A). All auto-
antibody binding intensities across all samples tested are pro-
vided in Table S3. We ranked autoantibody targets using fold-
change calculations between the MIS-C group and each of the
other groups of samples and looked for enriched Gene Ontology
(GO)-terms among the targets using gene set enrichment anal-
ysis (GSEA) (Subramanian et al., 2005). There were 26 GO-terms
that were enriched inMIS-C samples when compared to all other
groups (Figure 7B), and these involved lymphocyte activation
processes, phosphorylation signaling pathways, and heart
development (Figure 7C). The latter was interesting given that
myocarditis and impaired cardiac function are hallmarks of
MIS-C clinical presentation. We studied individual autoantibody
targets within this GO-term (Figure 7D) and identified endoglin, a
glycoprotein expressed by endothelial cells and necessary for
structural integrity of arteries to be differentially regulated among
groups of samples (Figure 7E). Loss of endoglin leads to the dis-
ease, hereditary hemorrhagic telangiectasia, a disease charac-
terized by multisystemic vascular dysplasia (McAllister et al.,
1994). Several, but not all, of the MIS-C patients had elevated
levels of autoantibodies targeting endoglin above the average
levels seen in healthy controls with a couple of exceptions (Fig-
ure 7E). A subset of Kawasaki disease patients also had elevated
levels of autoantibodies to endoglin (Figure 7E). Endoglin protein
expression is seen predominantly in the vascular endothelium,
with the heart muscle having the highest mRNA expression ofin PC2. p values for mean comparisons between MIS-C and Kawasaki disease





































































































































































Figure 5. Immunomodulatory Treatment in Patients with MIS-C
(A) Timelines for individual MIS-C patients (n = 13) indicating date of symptom debut, immunomodulatory treatment regimen, and date of blood sampling. Two
patients lacking clinical treatment data were blood sampled prior to treatment.
(B) Volcano plot showing fold-change (post-/pre-treatment) versus p value for 7 patients with multiple samples.
(C) Top markers of treatment response in MIS-C patients. Fold-change pre/post treatment (p < 0.05, false discovery rate [FDR], 1%).
See also Figure S2.
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OPEN ACCESSArticleall tissues (Uhlén et al., 2015). We also measured plasma levels
of endoglin, but these levels were elevated in Kawasaki and
MIS-C patients as compared to healthy children, possibly indi-
cating that autoantibodies to endoglin are not the cause of tissue
damage, but rather a consequence thereof (Figure 7F). It is inter-
esting to investigate a possible role for this protein and anti-
bodies targeting it, in the context of MIS-C and Kawasaki dis-ease pathogenesis or as a possible biomarker of endothelial
damage that could be useful to monitor in these patients.
Among the other enriched GO-terms, the majority involved
signal transduction and, in particular, signals propagated by
phosphorylation of tyrosine and serine residues. GO:
0018100105 is one example with clear overrepresentation
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Figure 6. Serological Responses and Prior Immunity in Kawasaki and MIS-C
(A) Anti-SARS-CoV-2 S1/S2 IgG antibodies in patients with mild infection (n = 26) and MIS-C (n = 4).
(B) VirScan analysis of IgG responses to 93,904 epitopes of 206 viruses in healthy (n = 19), CoV-2 infected (n = 11), Kawasaki disease (n = 27), and children with
MIS-C (n = 3). Virus scores is a function of the number of targeted epitopes per virus, and the heatmap shows the top 46 viruses with top average virus scores.
(C) The virus scores of coronaviruses available in the VirScan library, shown across individual children divided by disease groups.
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OPEN ACCESS Articlewith mild SARS-CoV-2 infection. We found several autoanti-
bodies in this category that were exclusively seen in MIS-C-pa-
tient samples and none of the other groups. Antibodies to
MAP2K2, and antibodies to three members of the Casein ki-
nase family (CSNK1A1, CSNK2A1, CSNK1E1) are notable ex-
amples (Figure 7G). The latter groups of autoantibody targets
are interesting in the context of SARS-CoV-2 infection, because
a recently published analysis of global phosphorylation patterns
in SARS-CoV-2 infected cells reported strong upregulation of
casein-kinase 2 activity, and potent antiviral activity of a drug,976 Cell 183, 968–981, November 12, 2020silmitasertib, inhibiting this kinase (Bouhaddou et al., 2020).
This finding, in combination with our results here, suggests
that the casein-kinase 2 pathway is important in viral replica-
tion, and possibly, autoantibodies to intermediates within these
related pathways arise during acute SARS-CoV-2 infection and
have play a role in MIS-C development thereafter in a subset of
previously infected children. These possible autoantibody tar-
gets are also broadly expressed across tissues, which is in
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Figure 7. Autoantibodies in MIS-C, Kawasaki, and Healthy Children
(A) Overall antibody binding intensities against 9,341 antigens from 7,669 human proteins in healthy children (n = 11), CoV-2+ (n = 5), MIS-C (n = 12), and Kawasaki
(n = 28) violin plots colored by sample group.
(B) Venn diagram showing 26 enriched GO-terms across MIS-C versus healthy, Cov-2+, and Kawasaki disease children.
(legend continued on next page)
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OPEN ACCESS ArticleNext, we decided to contrast autoantibody profiles in MIS-C
and Kawasaki disease patients given that there are similarities
in the presentation of these conditions, but there are also clear
differences. Kawasaki disease involves inflammation of me-
dium-sized arteries such as the coronary arteries, whereas
MIS-C patients seem to havemore diffuse presentation involving
intestine, myocardium, and brain. In our cohort, we found that
Kawasaki disease patients have elevated plasma biomarkers
of arterial damage as compared to MIS-C patients. We
compared the autoantibodies profiles to identify the most
different autoantibody targets between Kawasaki andMIS-C pa-
tients (Figure 7H). Although there were a number of differentially
regulated targets, autoantibodies to EDIL3 were most clearly
overexpressed in Kawasaki disease patients as compared to
MIS-C (Figure 7H). The gene encoding this protein has previously
been associated with Kawasaki disease (Jiang et al., 2017), and
the target protein is a structural glycoprotein in arterial vessel
walls that is regulated in response to vascular injury. One func-
tion of EDIL3 is to inhibit inflammatory cell recruitment and
extravasation across the endothelium, and when EDIL3 is dis-
rupted in mice, there is increased tissue infiltration of neutrophils
and elevated inflammatory responses (Choi et al., 2008).
Whether such autoantibodies to EDIL3 are pathogenic in Kawa-
saki disease remains to be determined.
Collectively, our findings show that MIS-C is a hyperinflamma-
tory disease with a qualitatively different inflammatory response
as compared to what is seen in acute SARS-CoV-2 infection and
is also different from the hyperinflammation in children with Ka-
wasaki disease. T cell differences can be seen, but are uncertain,
given differences in age between MIS-C and Kawasaki disease
patients. Serological responses to SARS-CoV-2 are seemingly
normal in MIS-C patients, but pre-existing immunity to related
coronaviruses is lower. A number of candidate autoantibodies
are identified for future studies of MIS-C pathogenesis.
DISCUSSION
The SARS-CoV-2 virus infects children at a similar rate as
adults (Jones et al., 2020), but fortuitously, the disease
COVID-19 is very mild in the overwhelming majority of infected
children (Brodin, 2020). Despite the mild COVID-19 in children,
recent reports of severe hyperinflammatory disorders devel-
oping 1–2 months after the acute infection with SARS-CoV-2
are cause for much concern. This MIS-C associated with
COVID-19, also called pediatric multisystem inflammatory syn-
drome, temporally associated with COVID-19 (PIMS-TS), has
now been reported in hundreds of children worldwide (Cheung
et al., 2020; Moraleda et al., 2020; Riphagen et al., 2020; Ver-
doni et al., 2020; Whittaker et al., 2020). The pathogenesis is
under intense investigation but so far remains elusive. One(C) The 26 GO terms enriched in MIS-C versus all other groups listed.
(D) GSEA plot for GO:0007507 heart development.
(E) Autoantibodies targeting the glycoprotein endoglin (CD105). p value compari
(F) Plasma endoglin levels measured by ELISA in plasma samples.
(G) Four candidate antigens bound by autoantibodies across the four patient gro
(H) Volcano plot showing fold-change differences in autoantibody signals betwee
antigens have p < 0.05 (FDR, 1%). EDIL3 is the single most overrepresented pro
See also Table S3.
978 Cell 183, 968–981, November 12, 2020study has found evidence of microangiopathy in MIS-C (Diorio
et al., 2020), and a recent autopsy study of a child who died
from MIS-C revealed abundant viral particles across a number
of tissues, possibly suggestive of a ‘‘second-hit’’ virus-medi-
ated pathology (Dolhnikoff et al., 2020). At the same time, chil-
dren with MIS-C typically respond well to aggressive immuno-
modulatory and anti-inflammatory therapies, which is unlikely
to be effective if pathology was mediated by the virus rather
than the immune system.
Here, we have combined several high-dimensional analysis
methods to uncover multiple aspects of the hyperinflammatory
response in children with MIS-C. We find similarities with the in-
flammatory response seen in children with Kawasaki disease,
but also important differences, such as the IL-17A-mediated hy-
perinflammation in Kawasaki disease, but notMIS-C. In addition,
differences in T cell subsets and cytokinemediators placeMIS-C
at the intersection of Kawasaki disease and acute SARS-CoV-2
infection immune states in children as well as the hyperinflam-
mation seen in adults with severe COVID-19. We also find higher
levels of biomarkers associated with arteritis and coronary artery
disease in Kawasaki disease than in MIS-C, suggesting a more
diffuse endothelial involvement and immunopathology in MIS-
C than in Kawasaki disease. Finally, we perform global autoanti-
body screening and find binding of autoantibodies to proteins
involved particularly in immune cell signaling, and structural pro-
teins in heart and blood vessels. These data suggest possible
targets of autoimmune attack. The hypothesis that autoanti-
bodies contribute to the pathology in MIS-C is supported by
the efficacy of intravenous immunoglobulin in MIS-C, a common
approach to activate inhibitory Fc-receptors and prevent mem-
brane-attack complexes by complement factors and thereby
mitigating autoantibody-mediated pathology (Kazatchkine
et al., 2001).
Our results showing lower naive CD4+ T cell, TFH, and in-
creases in central and effector memory subpopulations in MIS-
C as compared to Kawasaki disease patients could be partially
explained by differences in patient age, because immune cell
proportions change with age, even in healthy children (Olin
et al., 2018; Schatorjé et al., 2012). We did, however, see that
these cell population differences remained even when
comparing against additional older healthy controls, comparable
in age to the MIS-C patients. Several studies have indicated
defective T cell responses as a key element of severe COVID-
19 disease in adult patients (Vardhana and Wolchok, 2020).
We find expanded CD57+ CD4+ T cells often representing immu-
nosenescent and dysregulated T cells in both MIS-C and SARS-
CoV-2+ children with mild infections, suggesting that this might
be a consequence of the SARS-CoV-2 infection. Additional
studies in mild, and especially asymptomatic, COVID-19 cases
will be required to investigate this further.ng means in healthy children and MIS-C (FDR, 1%).
ups but at highest levels in MIS-C children.
n Kawasaki disease (n = 28) and MIS-C (n = 13). Purple and annotated target
tein in Kawasaki disease.
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atypical Kawasaki disease given the overlap in presentation be-
tween these groups of patients. Our data present a more com-
plex picture with both shared features and stark differences
that should influence treatment strategies for these conditions.
Kawasaki disease, but not MIS-C, is associated with robust IL-
17A-mediated inflammation, and IL-17A blocking agents, such
as secukinumab (Hueber et al., 2010), could be considered in
severe Kawasaki disease patients in future trials but perhaps
less relevant to MIS-C. Children with MIS-C in this study
were treated with a combination of intravenous immunoglobu-
lins (IVIGs), corticosteroids, and recombinant IL-1-receptor
antagonist, IL1RA (anakinra). The profiles of seven cytokines
indicated treatment responses and can be useful to monitor
in MIS-C patients undergoing treatment (Figures 5B and 5C).
Autoantibodies represent a possible pathogenic mechanism
in MIS-C and Kawasaki disease. IVIGs can neutralize some of
the immunopathological effects of autoantibodies, whereas
IL-1RA neutralizes strong IL-1 response elicited by endothelial
cells that are damaged by autoantibodies and complement.
Corticosteroids provide more general immunosuppression but
the mechanism of action in MIS-C for these treatments remains
to be determined. Other treatment strategies reported by other
groups include TNF-a blockade (infliximab) (Whittaker et al.,
2020), but when comparing plasma TNF-a levels in MIS-C pa-
tients to adults with acute COVID-19, TNF-a levels are much
lower in MIS-C (Figure 2), and comparable to healthy children,
we find no elevated levels (Figure S2B), suggesting that TNF-
a-blockade might not mitigate the hyperinflammation in MIS-
C. IL-6 blockade has been used in acute COVID-19 and in
MIS-C, but in our MIS-C patients, plasma levels of IL-6 were
highly variable and often normal (Figure 4C).
The autoantibody profiling presented here revealed a number
of possible autoantibody candidates. It is worth noting that the
result is not as clear, because the pathogenic autoantibodies
seen in well-established autoimmune disorders, such as auto-
immune thyroiditis or Addison’s disease, or in patients with
loss of tolerance due to AIRE deficiency (autoimmune polyen-
docrine syndrome type-1 [APS1]) (Landegren et al., 2016).
The results here are more diffuse, with many antigens targeted
and only a few shared across MIS-C patients as compared to
other patient groups. One caveat of these types of arrays is
the incorrect structure of some target antigens, and another
caveat is the inability of the secondary antibody to detect path-
ogenic autoantibodies of different classes than IgG, such as
IgA. Given that the initial immune response is likely elicited in
the respiratory or intestinal mucosa, IgA antibodies are of inter-
est, and IgA antibodies have been directly implicated in Kawa-
saki disease pathogenesis (Shulman and Rowley, 2015).
Despite these caveats, there are a number of possible autoan-
tibodies with pathogenic potential detected in the MIS-C pa-
tient cohort herein. Overall, the data presented here suggest
novel directions for future work toward more mechanistic un-
derstanding of the immunopathology in MIS-C, its underlying
immune perturbation, and development of better immunomod-
ulatory therapies for mitigating the hyperinflammatory disease
and long-term tissue damage in such rare children severely
affected by COVID-19.Limitations of Study
One caveat of this study was the limited sample size for children
with MIS-C (n = 13), and analyses with children with SARS-CoV-
2 infection (n = 5) in Figure 7. We also had a limited amount of
paired pre-/post-treatment samples from children with MIS-C,
which limited our power to understand MIS-C recovery post-
treatment. Future work will need to focus on understanding the
pathogenesis of MIS-C and Kawasaki disease, respectively,
and a more definitive understanding of the relevant autoantigens
involved. We have not been able to investigate a possible ‘‘sec-
ond hit’’ of viral replication in MIS-C or possible viral reservoirs
driving hyperinflammation. This will require more work in the
future.
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permits. Such requests should be directed to the lead contact author.
Data and Code Availability
Original data have been deposited to Mendeley Data: http://dx.doi.org/10.17632/ds6g796xyg.1. Scripts to reproduce the analyses
presented in each figure of the paper are available at https://github.com/Brodinlab/MIS-C_manuscript.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Study Participants and Sample Collection
44 SARS-CoV-2 infected children were enrolled within the CACTUS study at Bambino Gesù children hospital between March 17th
and May 15th 2020. Diagnostic tests for SARS-CoV-2 infection are reported below. Three of the 44 Italian children found
to be SARS-CoV-2+ by PCR herein were classified as having MIS-C. In addition, we enrolled 10 children at the Karolinska
University Hospital fulfilling the same MIS-C WHO criteria (https://www.who.int/news-room/commentaries/detail/
multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19). A total of 41 children with CoV2+ (23 males, 18
female) and 13 children with MIS-C (8 males, 3 female) were analyzed in this study. In summary this states that children and adoles-
cents between 0 and 19 years old, with fever > 3 days, and displaying two of the following signs: i) rash or bilateral non purulent
conjunctivitis or mucocutaneous inflammation signs, ii) hypotension or shock, iii) Features of myocardial dysfunction, pericarditis,
valvulitis, or coronary abnormalities (including ECHO findings or elevated Troponin/NT-proBNP), iv) evidence of coagulopathy (by
PT, PTT, elevated d-Dimers), v) acute gastrointestinal problems (diarrhea, vomiting, or abdominal pain); AND elevated markers of
inflammation such as ESR, C-reactive protein, or procalcitonin; AND no other obvious microbial cause of inflammation, including
bacterial sepsis, staphylococcal or streptococcal shock syndromes; AND evidence of SARS-CoV-2 infection (RT-PCR or serology
positive), or likely exposure to COVID-19 patient. Twenty-eight children diagnosed with Kawasaki disease (14 male, 14 female) were
enrolled during acute phase at the Academic Department of Pediatrics, Division of Immune and Infectious Diseases at Bambino Gesù
Children’s Hospital (OPBG) between September 2017 and June 2019, well before the COVID-19 pandemic hit Europe. KD diagnosis
wasmade according to the 2017 criteria of the American Heart association, including both the complete and incomplete types. Fever
onset was considered as the first day of the acute KD phase. Nineteen healthy controls (HC) were included in the study. Demographic
and clinical data of all the patients are summarized in Figure 1B. Swedish patients are included in accordance with the Ethical permit
(EPM ID: 2020-01911). Italian children are included in accordance with a study protocol approved by the OPBG Ethics Committee.
Informed consent was obtained from parents or guardians of all patients both in Sweden and Italy. APS-1 patient samples were
included as positive controls in autoantibody analyses and their sampling and analyses were covered by Ethical permit (EPM ID:
2016/2553-31/2).
METHOD DETAILS
Confirmation of SARS-CoV-2 Infection
All patients enrolled in the CACTUS study with nasopharyngeal swab tested positive for SARS-CoV-2 nucleic acid using reverse-
transcriptase qualitative PCR assay were considered confirmed cases of SARS-CoV-2 infection. In addition, all serum samples of
COVID-19 patients in Italy were investigated for presence of SARS-CoV-2 antibodies. IgG antibodies were quantitatively tested
by LIAISON SARS-CoV-2 S1/S2 IgG test (Diasorin).
Serum Protein Profiling
Serum proteins were analyzed using a multiplex technology based upon proximity-extension assays (Lundberg et al., 2011). We
measured 180 unique proteins using the Olink panels of Immune Response and Inflammation (Key Resources Table). Briefly,
each kit consisted of a microtiter plate for measuring 92 protein biomarkers in all 88 samples and each well contained 96 pairs of
DNA-labeled antibody probes. To minimize inter- and intra-run variation, the data were normalized using both an internal control
(extension control) and an inter-plate control, and then transformed using a pre-determined correction factor. The pre-processed
data were provided in the arbitrary unit Normalized Protein Expression (NPX) on a log2 scale and where a high NPX represents
high protein concentration.
VirScan
We investigated and compared antiviral antibody repertoires (IgG) of MIS-C, CoV-2+, Kawasaki and healthy children with VirScan, a
viral epitope scanning method that relies on bacteriophage display and immunoprecipitation and we used the method as previously
described (Pou et al., 2019; Xu et al., 2015). Briefly, VirScan uses a library of bacteriophages presenting 56-amino-acid-long linear
peptides that overlap by 28 amino acids to collectively encompass the entire genomes of 1,276 viral strains from 206 viral species
known to infect human cells. After virus inactivation and normalization to total IgG concentration, plasma samples were incubated
with the phage library to form IgG-phage immunocomplexes, later captured by magnetic beads. Collected bacteriophages wereCell 183, 968–981.e1–e4, November 12, 2020 e2
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peptide hits that do not share epitopes, and it is incremented by 1 when a hit is enriched in the ‘output’ compared with the ‘input’.
Background noise is commonly observed in bacteriophage display assays. In order to minimize false-positive hits, we removed hits
occurring as a consequence of unspecific binding to beads only (blank reactions without antibodies). Moreover, we also removed
cross-reactive antibodies by ignoring hits that share a subsequence of at least seven amino acids with any other enriched hit found
in the same sample.
Autoantibody Profiling
We performed autoantibody profiling on samples from healthy children (n = 11), children with CoV-2+ (n = 5), children with MIS-C (n =
12) and children with Kawasaki (n = 28) in two batches. Serum autoantibody reactivity was studied using full-length human protein
arrays (ProtoArray v5.1, PAH05251020, ThermoFisher) (Zhu et al., 2001). Protein arrays were probed with serum at a dilution of
1:2000, and otherwise followed the protocol provided by the manufacturer for immune response biomarker profiling. Protein arrays
were first incubated with blocking buffer (PA055, Life Technologies) for 1 hour, followed by 90 min incubation with serum at 1:2000
dilution, and 90 min incubation with detection antibodies: Alexa Fluor 647 goat anti-human IgG antibody (A21445, ThermoFisher) at
1:2000 dilution and Dylight 550 goat anti-GST (#DY550011-13-001, Cayman Chemicals) at 1:10,000 dilution. The LuxScan HT24
(BioCapital) microarray scanner was used.
ELISA
Serum endoglin levels (CD105) were determined using manufacturer’s instruction (Key Resources Table). Briefly, samples were heat
inactivated (56C for 30 min) and 50mL was used for ELISA-based quantification of Endoglin levels. Samples with out-of-range
values were diluted and measured again.
Flow Cytometry
Blood samples from KD and SARS-CoV-2+ patients were collected at the time of diagnosis and with regards to KD, always before
Intravenous immunoglobulin administration. After ficoll, PBMCs and plasma samples were stored in liquid nitrogen or at 20C,
respectively, in Nunc Cryotubes (Merk KGaA, Darmstadt, Germany). Flow cytometry was performed for 30 patients, and isolated
PBMCs were stained with LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit (for 633 or 635 nm excitation, ThermoFisher, Waltham,
Massachusetts, US) for 15 minutes at 4C. Then, the cells were washed in wash buffer (phosphate-buffer saline with 1% bovine
serum albumin) and stained for 30 minutes at 4C with anti-hCD3 PE-CF594, anti-hCD4 BV510, anti-hCD25 PE, anti-hCD45RO-
PerCP-Cy 5.5, anti-hCD27 V450, anti-hCD57 APC, anti-hCD185(CXCR5) BV605 (all from BD Biosciences, Milan, Italy), anti-
hCD127 PE-Cy7, anti-hPD1 BV711 (all from Biolegend, San Diego, CA). Data acquired by CytoFLEX cytometer (Beckman Coulter,
Milan, Italy) were analyzed by FlowJo software v.10 (Treestar Software, Ashland, Oregon, USA).
QUANTIFICATION AND STATISTICAL ANALYSIS
Serum Protein Analyses
Plasma protein analyses in Figure 2 were performed using samples from children withMIS-C (n = 13), children with Kawasaki (n = 28),
adult CoV-2+ non-ICU (n = 7 subjects, 14 time points total), and adult CoV-2+ ICU (n = 10 subjects, 43 time points total). In order to
compare Adult CoV-2+ cases with Kawasaki and MIS-C children, bridge normalization was used due to available bridge samples
between assays regarding children. Bridge normalization was done with the function olink_normalization() fromOlinkAnalyze R pack-
age. A 30% LOD cutoff was used to filter out proteins for all Olink plates. Then both plates were filtered for matching proteins across.
The normalized combined plate with children cases as well as the plate containing the Adult CoV-2+ cases were scaled within each
set to unit variance (z-score) before merging. For the PCA and PC contribution plots, both were done using the library factoextra and
only the top 20 contributions were displayed in the contribution plot. Plasma protein analyses in Figure 4 were performed using sam-
ples from healthy children (n = 12), children with SARS-CoV-2 without hyperinflammation (n = 41), children with MIS-C (n = 21, pre-
treatment n = 11, post-treatment n = 7), and children with Kawasaki (n = 28). The four proteins (IL10, IL6, CCL11, IL5) that overlapped
between Olink Immune Response and Inflammation panels were averaged. Proteins with > 30%measurements below the threshold
of detection were filtered out, resulting in 120 and 133 plasma proteins used for PCA in Figures 2 and 4 respectively. Because Olink
data from Figure 4 was run in two batches, bridge normalization was applied using function olink_normalization from R package Olin-
kAnalyze, followed by batch correction using the function removeBatchEffect fromR package limma. The analyzed Olink parameters
for Figures 2 and 4, and their mean NPX and standard deviations are provided (Tables S1 and S2). For analyses in Figure 5, seven
paired pre/post treatment MIS-C samples were compared.
Virscan Data Analysis
For each sample, sequencing reads were first mapped to the original library sequences with Bowtie, and the number of reads of each
peptide in the original library were counted with SAMtools. A zero-inflated generalized Poisson distribution was applied to fit the fre-
quency of peptides, and log10ðpÞ was calculated for each peptide as the probability of enrichment. Peptides with log10ðpÞ larger
than 2.3 in both technical replicates were considered to be significantly enriched. Among the significantly enriched peptides, thosee3 Cell 183, 968–981.e1–e4, November 12, 2020
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in only one sample. The remaining enriched peptides were used to calculate the virus scores. To remove the hits caused by cross-
reactive antibodies, we first sorted the virus by their total number of enriched peptides in descending order. For each virus in this
order, we iterated through all the enriched peptides and removed those that shared a sequence of more than 7 amino acids with
any previously observed peptides in any virus of the same sample. The remaining enriched peptides were considered specific
and their number is the virus score for the virus. Afterward, we filtered out the outlier viruses with Virus Scores > 1 in only sample
and negative Virus Scores in all others. We also filtered out viruses with Virus Scores < 2 in all samples.
Autoantibody Analyses
All analyses of autoantibody reactivities were performed using background-subtracted mean signal values of protein duplicates of
the human IgG channel. Samples were quantile-normalized, and technical duplicates were averaged. For comparisons of autoanti-
body target reactivity betweenMIS-C and other groups (healthy control, CoV-2+ andKawasaki), differential expression was run using
deseq function of the R package DESeq2. Ranked lists were obtained for each comparison to MIS-C (contrasts) and used for GSEA.
GSEA was run on the ranked list of unique targets using the gseGO() function of the clusterProfiler R package.
Flow Cytometry Data Analysis
Statistical comparisons between two groups on flow cytometric frequencies were performed with t test if both distributions were
approximately normal or, conversely, with the Wilcoxon nonparametric test. In both cases, the normality of the distributions was
testedwith the D’Agostino-Pearson test. P values less than 0.05 were considered to be statistically significant. MOFAwas performed
with the MOFA+ package (Argelaguet et al., 2019) (version 1.0) in the R statistical environment. Data analysis was performed using R
(version 3.6.2).Cell 183, 968–981.e1–e4, November 12, 2020 e4
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Figure S1. Multiomics Immune System Differences among Disease Groups, Related to Figure 3
(A) Gating of CD4- T cell subsets. (B) Frequency of CD4- T cells across disease groups. (C) Naive and memory phenotype CD4- T cells. (D) Fraction of variance
explained by 10 latent factors, (E) Fraction of variance explained by data type, (F) Samples distributed across the top five latent factors. (G) Top contributing
















Figure S2. Related to Figure 4
(A) Plasma MMP-1 and MMP-10 across disease groups. (B) Plasma TNFa levels in patient groups. NPX is Normalized expression level.
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